MoonLake Immunotherapeutics (MLTX) Earnings Call Transcripts

MoonLake Immunotherapeutics's Latest Earnings Call - June 22, 2026

MoonLake Immunotherapeutics reported its Q2 2026 earnings with a focus on the dermatology indication of hidradenitis suppurativa (HS). The company highlighted the completion of Phase III trials for its lead asset, sonelokimab, showing promising efficacy and safety data. Revenue and earnings details were not disclosed in the transcript. Management emphasized the upcoming BLA submission by the end of Q3 2026, aiming for a potential launch in 2027. The company did not provide specific revenue or earnings guidance but outlined a robust commercialization strategy.

Reported metrics

Guidance from management

MoonLake plans to submit the BLA by the end of Q3 2026, with a potential launch in late 2027. They are exploring a priority review option, which could accelerate the timeline by 3-4 months.

What management said

So we have a couple of questions here related to the VELA-TEEN study. One of the questions here from Rami Katkhuda, LifeSci Capital. The adolescent HS data appear very strong despite the small sample size. How much this benefit do you attribute to earlier-stage disease? And do you expect the VELA-TEEN data on the label as well? Maybe Kristian, do you want to take this?

All right. Next, we have a couple of questions here on the safety side of things. One hear from Phil Nadeau from TD Cowen. Can you discuss your confidence that you won't get a warning for suicidal ideation? I thought there was no signal in your trials our understanding that the FDA often defaults to class labeling for rare adverse events. Have you discussed the SIV warning with the FDA? And similar questions we recei...

What analysts pressed on

Analysts questioned the potential inclusion of VELA-TEEN data in the label and the impact of early-stage disease treatment on efficacy. Concerns were also raised about the competitive landscape in HS and the differentiation of sonelokimab's safety profile.

Main topics on the call

• Phase III HS Trial Results — Sonelokimab demonstrated a 67% HiSCR75 response rate after one year, with 33% achieving HiSCR100. Management emphasized the drug's potential as a 'best-in-class' treatment for HS, citing 'a very unique benefit ratio for ...
• BLA Submission and Label Strategy — MoonLake plans to submit a BLA by the end of Q3 2026, with the potential for a priority review. The company aims for a label that includes HiSCR75 as a primary endpoint and patient-reported outcomes, which could differen...
• Commercialization Strategy — The company is preparing for a U.S. launch, emphasizing the $10-15 billion market opportunity in HS. They highlighted a 'very high willingness to prescribe' from dermatologists and a strong balance sheet to support comme...
• Adolescent HS Trial (VELA-TEEN) — The VELA-TEEN trial showed strong efficacy in adolescents, with 60-70% achieving HiSCR75. Management noted the potential for a broader label that includes adolescent data.

Read the full MoonLake Immunotherapeutics transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 3 MoonLake Immunotherapeutics earnings call transcripts on record, spanning September 29, 2025 to June 22, 2026. Based on this history, MoonLake Immunotherapeutics reports semi-annually. The most recent call on file is dated June 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MLTX

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

3

First call

September 29, 2025

Most recent

June 22, 2026

Reporting cadence

semi-annually